The incidence of uveitis after systemic lymphoma in Taiwan
An 18-year nationwide population-based cohort study

Yu-Te Huang, MD\textsuperscript{a}, Chun-Ju Lin, MD\textsuperscript{a,b,c,*}, Pei-Lun Liao, BS\textsuperscript{d}, Min-Yen Hsu, MD, PhD\textsuperscript{d,f}, Cheng-Hsien Chang, MD, PhD\textsuperscript{a,g}, Peng-Tai Tien, MD\textsuperscript{d,h}, Chun-Ting Lai, MD\textsuperscript{a}, Ning-Yi Hsia, MD\textsuperscript{a}, Henry Bair, BS\textsuperscript{a,i}, Huan-Sheng Chen, MD\textsuperscript{d}, Chun-Chi Chiang, MD, PhD\textsuperscript{a,b,c}, Yi-Yu Tsai, MD, PhD\textsuperscript{a,b,c}

Abstract

Although uveitis can be an intraocular presentation of systemic lymphoma, it may be associated with direct lymphomatous infiltration and immune-mediated alterations. There have been no published studies describing the incidence of uveitis after systemic lymphoma. We conducted a nationwide cohort study to investigate the incidence of uveitis after systemic lymphoma diagnosis in Taiwan. Data were collected from the Taiwan National Health Insurance system and included patients newly diagnosed with systemic lymphoma between 2000 and 2017. We observed the risk of uveitis among study population since the index date until December 2017. The incidence of systemic lymphoma patient and paired comparison was identified by time distribution matching and individual paired with sex and age. Subsequent propensity score matching (PSM) was used to select the 1:1 of systemic lymphoma patient and paired comparison by greedy algorithm with caliper of 0.05. The multiple Cox proportional hazard regression model was used to compare the developmental risk of uveitis (time-to-uveitis) between the systemic lymphoma and non-systemic lymphoma, while controlling for selected covariates. After time distribution matching, we selected 6846 patients with systemic lymphoma, and 54,768 comparisons. Among patients with systemic lymphoma groups, there were more men than women (52.94% vs 47.06%) and the mean age was 53.32±21.22 years old. Systemic lymphoma incidence rates (per 10,000 person-months) of uveitis were 1.94 (95% confidence interval [CI], 1.60–2.35) in the systemic lymphoma cohort and 1.52 (95% CI, 1.42–1.63) in the non-systemic lymphoma cohort. Compared with the non-systemic lymphoma cohort, adjusted hazard ratio (aHR) of developing uveitis were 1.24 (95% CI, 1.00–1.52) in people with systemic lymphoma. But not significant in after PSM, aHR of developing uveitis were 1.17 (95% CI, 0.90–1.53). This 18-year nationwide population-based cohort study in Taiwan, showed that the risk of uveitis in patients’ systemic lymphoma was not significantly higher than non-systemic lymphoma after PSM. In elderly and rheumatic patients with intraocular inflammation, it is important to first exclude uveitis masquerade syndrome, which could be a harbinger of intraocular involvement from systemic lymphoma. Further large-scale prospective clinical studies to investigate whether systemic lymphoma influences the incidence of uveitis are warranted.

Abbreviations: ASD = absolute standardized difference, aHR = adjusted hazard ratio, CI = confidence interval, ICD9-CM = International Classification of Diseases, 9th Revision, Clinical Modification, LHID = Longitudinal Health Insurance Database, NHIRD = National Health Insurance Research Database, PSM = propensity score matching.

Keywords: cohort study, intraocular inflammation, systemic lymphoma, uveitis
1. Introduction

Lymphoma is a heterogeneous group of blood malignancies that develop from lymphocytes. Lymphomas are the ninth most common cancer and constitute 3.2% of malignant tumors, which also account for 2.7% of cancer deaths worldwide and can occur at any age.1,2 Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise.1,2 They may be broadly divided into non-Hodgkin (90%) and Hodgkin (10%) types. Most lymphomas (90%) are of B cell origin but can also be T cell or natural killer cell.3 Each type of lymphoma grows at a different rate and responds differently to treatment.2

Uveitis refers to sight-threatening intraocular inflammation that affects both the uveal tract and adjacent structures including the sclera, cornea, vitreous, retina, and optic nerve.4 Patients of uveitis comorbidant with systemic lymphoma have been reported.4–9 Ocular symptoms of systemic lymphomas are non-specific and often mimic uveitis.9–16 Malignant lymphomas involving the eye and surrounding structures are rare, representing less than 10% of extranodal lymphoma.9 As the uvea is rich in blood vessels, immune system activation in 1 organ can result in hematogenous spread of inflammatory cells and cytokines into the eyes. In cases of intraocular involvement of systemic lymphoma, anterior or posterior intraocular inflammation may occur (masquerade syndrome).8–16

No published study has investigated the incidence of uveitis after systemic lymphoma. Therefore, we conducted a nationwide cohort study by analyzing the claims data from the Taiwan National Health Insurance Research Database (NHIRD) during a follow-up period from 2000 to 2017 with ICD-9 codes to explore the risk of uveitis in patients with systemic lymphoma and non-systemic lymphoma in the Taiwanese population.

2. Materials and methods

2.1. Data source

Taiwan’s Bureau of National Health Insurance set up the NHIRD based on the single-payer National Health Insurance program. This program was inaugurated on March 1, 1995 and provides coverage to over 99% of all residents in Taiwan. We obtained a Longitudinal Health Insurance Database 2005 version (LHID), which includes 2,000,000 insured Registry for Beneficiaries. All medical claims included both inpatient and outpatient visits and medical treatment for each insured from January 1, 2000 to December 31, 2017 that were contained in the LHID. To comply with the Personal Information Protection Act, the identification of each insured in the LHID was re-coded. This study was also approved by the Institutional Review Board of Chung Shan Medical University Hospital (IRB CS1-20108), Taiwan.

2.2. Study subject

We collected patients who were newly diagnosed with systemic lymphoma (the International Classification of Diseases, 9th and 10th Revision, Clinical Modification [ICD-9-CM codes: 200, 201, 202, ICD-10-CM codes: C80, C81, C82, C83, C84, C85, C86, C88]) from 2000 to 2017. Patients with at least 1 medical visit or 1 hospital admission for systemic lymphoma were defined as new cases and the first date of diagnosis with systemic lymphoma was defined as the index date. Those with a diagnosis of systemic lymphoma prior to 2000 were excluded. The endpoint was a new diagnosis of uveitis (ICD-9-CM codes: 360.12, 363.0x, 363.1x, 363.20, 363.21, 363.22, 364.0x, 364.1x, 364.2x, 364.3, ICD-10-CM codes: H44.11, H30, H20). The follow-up was at the start of the index date until the first occurrence of uveitis, death, or December 31, 2017. Those with a history of uveitis before index date were excluded. Index date before 2000, and after 2016 were also excluded.

Controls were randomly selected from a population without histories of systemic lymphoma. The systemic lymphoma cohort was time distribution matching with the non-systemic lymphoma cohort to give a start point at a ratio of 1:8 by age (±1 years old) and sex. To prevent potential confounding bias, the systemic lymphoma cohort was matched with the non-systemic lymphoma cohort by propensity score matching (PSM) with a greedy matching algorithm at a 1:1 ratio, caliper of 0.05. Co-morbidities included hypertension, diabetes mellitus, stable coronary artery disease, hyperlipidemia, congestive heart failure, acute myocardial infarction, rheumatic disease, liver disease, liver cirrhosis, HIV, and tuberculosis.

2.3. Endpoint, demographic characteristics, and systemic lymphoma

The clinical endpoint was a diagnosis of uveitis. Patients with at least 2 medical visits for uveitis, which were separated for at least 7 days, were defined as the endpoint to ensure validity. All study subjects were followed from the index date until the first occurrence of uveitis, death, or December 31, 2017. In this study, the demographic characteristics included age group (<20, 21–40, 41–65, and >65 years old), gender, marital status, and education at the index date.

2.4. Statistical analysis

A chi-square test was used for the difference of demographic characteristics between the systemic lymphoma cohort and comparison cohort. The uveitis survival rates in the 2 groups were calculated using the Kaplan–Meier method and the log-rank test. The multiple Cox proportional hazard regression model was used to compare the incidence risk of uveitis (time-to-uveitis) between the systemic lymphoma and non-systemic lymphoma, while controlling for selected covariates.

To prevent potential confounding bias, the systemic lymphoma cohort was matched with the non-systemic lymphoma cohort by PSM with a greedy matching algorithm at a 1:1 ratio, caliper of 0.05. The goal is to approximate a random experiment, eliminating many of the problems that come with observational data analysis. P values <.05 were statistically significant for this study. All analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC).

3. Results

In this retrospective cohort study, a total number of 6846 patients with systemic lymphoma were enrolled in the study group, while another 54,768 individuals were sex age (±1 years old) matching at index date enrolled into the control group. After 1:1 PSM matching by sex, age, marital status, education, and co-morbidities yielded 6811 systemic lymphoma and non-systemic lymphoma. The flowchart of patient selection is shown in Figure 1. The baseline characteristics of all patients with systemic lymphoma and non-systemic lymphoma group in Table 1.
After time distribution matching, among patients with systemic lymphoma presenting, there were more men than women (52.94% vs 47.06%) and the mean age was 53.32 ± 21.22 (mean ± standard deviation) years old. After 1:1 PSM, we used absolute standardized difference assessment balance in among 2 groups, the absolute standardized difference of < 0.1 was mean a small difference (Table 1).

During the follow-up period, for patients with systemic lymphoma the incidence rate was 1.94 (95% confidence interval [CI]: 1.60–2.35) per 10,000 person-months, and without systemic lymphoma the incidence rate was 1.52 (95% CI: 1.42–1.63) per 10,000 person-months, there was significant difference of crude relative risk 1.27 (95% CI: 1.04–1.56). But after PSM the crude relative risk was not significantly 1.09 (95% CI: 0.83–1.41), the incidence rate was 1.95 (95% CI: 1.61–2.36), and 1.78 (95% CI: 1.48–2.13) per 10,000 person-months. The trend was similar in different models after adjusting for multiple potential risk factors including demographic data, systemic diseases, and socioeconomic status (Table 2).

The multip Cox proportional hazard regression model showed the adjusted hazard ratio (aHR) of uveitis for patients with systemic lymphoma was 1.24 (95% CI: 1.00–1.52) in before PSM, after PSM the aHR of uveitis for patients with systemic lymphoma was 1.17 (95% CI: 0.90–1.53). After PSM, patients aged 41 to 65 years (aHR: 3.05, 95% CI: 1.32–7.03) and age greater than 66 years old group (aHR: 3.31, 95% CI: 1.39–7.85) risk of uveitis was significantly higher than age ≤20 years old group, and patients with rheumatic disease (aHR: 1.85, 95% CI: 1.03–3.32) risk of uveitis was significantly higher than without rheumatic disease (Table 3).

4. Discussion
In this study, the occurrence of uveitis was significantly higher in those with systemic lymphoma compared to non-lymphoma individuals, after adjusting for multiple potential risk factors in the different models. However, after PSM, patients with systemic lymphoma were found to have no significantly higher incidence of uveitis, with the crude relative risk was 1.09 (95% CI: 0.83–1.41).

We can offer some speculations regarding the relationship between systemic lymphoma and uveitis. First, intraocular involvement of systemic lymphoma can present as intraocular inflammation simulating uveitis (masquerade syndromes) with manifestations including vitritis, intermediate uveitis, or sub-retinal plaque-like lesions.[22] When ophthalmologists encounter patients with intraocular inflammation in Taiwan, the ICD-9 diagnostic codes of uveitis would be usually used to indicate a diagnosis on a reimbursement claim for the arrangement of further examinations.

Another possible indirect connection are patients with sarcoidosis. Several studies strongly support the increased risk of lymphoma in patients with sarcoidosis.[17,18] The underlying sarcoidosis can present as sarcoïd uveitis during any stage of the disease. The term “sarcoidosis–lymphoma syndrome” was first suggested by Bichel and Brincker[19] in the 1960s and additional descriptions of this connection have been published.[20]

Several possible pathophysiologic mechanisms may explain the relationship between sarcoidosis and lymphoma. Global regulatory T-cell subset amplification can be found in sarcoidosis, which enhances proliferation of naïve and effector T cells producing interleukin-2. Interleukin-2 furthermore acts as a growth factor for B cells, and the proliferation might override endogenous regulatory mechanisms, eventually leading to their transformation into malignant B cells, which results in systemic lymphoma.[18] This hypothesis is hard to be verified in our studies due to the scarcity of sarcoidosis in Taiwan. In a report from the Taiwanese NHIRD, Taiwan has an overall sarcoidosis prevalence of 2.17 per 100,000 people per year, which is much lower than the prevalence in northern European databases (11–19 per 100,000 people per year).[21–23]

Other diseases that correlated with the occurrence of uveitis after systemic lymphoma prior to PSM were diabetes mellitus, stable CAD, hyperlipidemia, and rheumatic diseases. However, after PSM, only rheumatic diseases showed a significant correlation with uveitis. The association between rheumatic diseases and uveitis is reasonable since several rheumatic diseases are the etiologies of uveitis.

Age over 41-years-old was another risk factor identified in our study, which corresponded to the previous epidemiological study.[24,25] Several types of lymphoma can involve the eye and mimic uveitis. Systemic non-Hodgkin lymphoma mostly occurs in people aged 60 and older and more frequently involve the eye than Hodgkin lymphoma. Ocular involvement in Hodgkin lymphoma is relatively rare and usually occurs late in the course of the disease which demonstrates a bimodal distribution, with those between 20 and 30 years and those over 55 years of age having a higher risk.[2,3,10,11]

Prior studies concerning the epidemiology of uveitis have been involved different methodologies and databases. The incidence of uveitis has been estimated to be between 0.14 and 0.43 per 10,000 people per month, which was much lower than our present study (1.52–1.95 per 10,000 of population per month).[26,27] Even in the population older than 65 years, the
Table 1
Baseline characteristics.

|                          | Uveitis without systemic lymphoma | Uveitis with systemic lymphoma | ASD       |
|--------------------------|----------------------------------|-------------------------------|-----------|
|                          | Age-sex matching 8:1              | After PSM 1:1                  |           |
| N                        | 54,768                           | 6846                          | 6811      | 6811      | 0.0000 | 0.0000 |
| Year of index            |                                  |                               |           |
| 2000–2004                | 14,336 (26.18%)                  | 1702 (26.18%)                 | 1784      | 1787      | 0.0000 | 0.219  |
| 2005–2008                | 12,208 (22.29%)                  | 1526 (22.29%)                 | 1508      | 1520      | 0.219  | 0.219  |
| 2009–2012                | 11,832 (21.6%)                   | 1479 (21.6%)                  | 1479      | 1466      | 0.219  | 0.219  |
| 2013–2016                | 16,392 (29.93%)                  | 2049 (29.93%)                 | 2040      | 2038      | 0.219  | 0.219  |
| Sex                      |                                  |                               |           |
| Female                   | 25,776 (47.06%)                  | 3222 (47.06%)                 | 3192      | 3215      | 0.0000 | 0.006  |
| Male                     | 28,992 (52.94%)                  | 3624 (52.94%)                 | 3619      | 3596      | 0.0000 | 0.006  |
| Age at index (mean±SD)   | 53.29 ±21.21                     | 53.32 ±21.22                  | 54.29 ±21.01 | 53.37 ±21.22 | 0.0000 | 0.029  |
| ≤20                      | 4552 (8.31%)                     | 569 (8.31%)                   | 543 (7.97%) | 567 (8.32%) |
| 21–40                    | 10,505 (19.18%)                  | 1318 (19.25%)                 | 1233 (18.1%) | 1303 (19.13%) | 0.0000 | 0.029  |
| 41–65                    | 21,859 (39.91%)                  | 2715 (39.66%)                 | 2703 (39.69%) | 2703 (39.69%) | 0.0000 | 0.029  |
| >65                      | 17,852 (32.6%)                   | 2244 (32.78%)                 | 2332 (34.24%) | 2238 (32.86%) | 0.0000 | 0.029  |
| Marital status           |                                  |                               |           |
| Unmarried                | 13,105 (23.93%)                  | 1598 (23.34%)                 | 1482      | 1577      | 0.024  | 0.024  |
| Married                  | 34,396 (62.8%)                   | 4344 (63.45%)                 | 4414      | 4355      | 0.024  | 0.024  |
| Divorced                 | 2866 (5.23%)                     | 404 (5.9%)                    | 401 (5.89%) | 401 (5.89%) |
| Widowed                  | 4401 (8.04%)                     | 500 (7.3%)                    | 514 (7.55%) | 498 (7.31%) |
| Education                |                                  |                               | 0.044     |           |
| Elementary school or below | 24,757 (45.4%)              | 2972 (43.41%)                 | 3048      | 2961      | 0.047  | 0.047  |
| Junior high school       | 8623 (15.74%)                    | 1090 (15.92%)                 | 1028      | 1084      | 0.047  | 0.047  |
| Senior high school       | 13,916 (25.41%)                  | 1706 (26.23%)                 | 1775      | 1788      | 0.047  | 0.047  |
| University/college or above | 7472 (13.64%)                | 988 (14.43%)                  | 960       | 978       | 0.047  | 0.047  |
| Co-morbidities           |                                  |                               |           |
| Hypertension             | 14,426 (26.34%)                  | 2287 (33.41%)                 | 2397      | 2278      | 0.036  | 0.036  |
| Diabetes mellitus        | 6780 (12.38%)                    | 1199 (17.51%)                 | 1235      | 1193      | 0.016  | 0.016  |
| Stable CAD               | 4574 (8.35%)                     | 798 (11.66%)                  | 831       | 793       | 0.017  | 0.017  |
| Hyperlipidemia           | 7234 (13.21%)                    | 1082 (15.8%)                  | 1141      | 1081      | 0.023  | 0.023  |
| Congestive heart failure | 1614 (2.95%)                     | 394 (5.76%)                   | 391       | 390       | 0.000  | 0.000  |
| AMI                      | 184 (0.34%)                      | 43 (0.63%)                    | 37        | 42        | 0.009  | 0.009  |
| Rheumatic disease        | 482 (0.88%)                      | 193 (2.82%)                   | 180       | 190       | 0.009  | 0.009  |
| Liver disease            | 4155 (7.59%)                     | 1305 (19.06%)                 | 1324      | 1280      | 0.016  | 0.016  |
| Liver cirrhosis          | 406 (0.74%)                      | 215 (3.14%)                   | 210       | 209       | 0.000  | 0.000  |
| HIV                      | 24 (0.04%)                       | 44 (0.64%)                    | 19        | 24        | 0.035  | 0.035  |
| Tuberculosis             | 244 (0.45%)                      | 156 (2.28%)                   | 131       | 142       | 0.011  | 0.011  |
| CCI score                | 4.291                            |                               | 3.250     |           |
| 0–2                      | 40,050 (79.56%)                  | 0 (0%)                        | 5697      | 0 (0%)    |           |
| 3–5                      | 4734 (8.64%)                     | 4939 (72.14%)                 | 887       | 4933      | 0.036  | 0.036  |
| 6–8                      | 710 (1.3%)                       | 837 (12.23%)                  | 167       | 832       | 0.011  | 0.011  |
| ≥9                       | 274 (0.5%)                       | 1070 (16.53%)                 | 60        | 1046      | 0.011  | 0.011  |

AMI = acute myocardial infarction, ASD = absolute standardized difference, CAD = coronary artery disease, HIV = human immunodeficiency virus, PSM = propensity score matching, SD = standard deviation.

Incidence rate was around 0.79 per 10,000 people per month, which is still lower than our present study.[26,27] Several reasons may explain the difference. First, access to health care is extremely convenient in Taiwan. Patients in this population with uveitis may be more likely to seek an ophthalmologist’s evaluation than patients in other populations studied. Second, since patients with systemic lymphoma regularly follow up in the health care system, we speculate that health awareness and willingness to accept referral with the presentation of ocular symptoms may be higher among these patients than the general population.

A previous NHIRD study in Taiwan, which reported average uveitis incidence was 0.93 cases per 10,000 person-months from 2003 to 2008 with the 95% CI ranged between 0.90 cases and 0.95 cases per 10,000 person-months.[24] The incidence was comparable to our study results when a similar aged group was selected. In the age group from 56 to 65 and older than 66 years-old, the incidence was 1.24 and 1.62 cases per 10,000 person-months which served as another evidence to the validity of the present study.

Several limitations remain in the current study. First, most of the biases came from the retrospective nature of this study. The usage of insurance claim database, rather than real medical documents, inevitably renders some important information unavailable, such as the severity of uveitis, the etiology of uveitis, and the disease status of systemic lymphoma. Nevertheless, the PSM process and multivariable analysis were used for further verification. Also, the sample size might also influence the results. Although NHIRD covered more than 99% of the cases in our population, a cross-national database could provide a more comparative observation and confirm the relationship of lymphoma and uveitis. Finally, only patients of uveitis suspected
by ophthalmologists were enrolled in the current study to gain the incidence of the diagnosis. Other patients who did not seek medical care may have contributed to an underestimation of the incidence of uveitis.

| Variable | Adjusted hazard ratio (95% CI) | Before PSM | After PSM |
|----------|--------------------------------|------------|-----------|
|          |                                | Non-systemic lymphoma | Systemic lymphoma | Non-systemic lymphoma | Systemic lymphoma |
| N        |                                | 54,768     | 68,46     | 6811 | 6811 |
| Follow up person months |                                | 5,302,788 | 545,111 | 649,434 | 543,220 |
| New diagnosed uveitis |                                | 106       | 115       | 106  | 106  |
| Incidence rate (95% CI) |                                | 1.52 (1.42–1.63) | 1.94 (1.60–2.35) | 1.78 (1.48–2.13) | 1.96 (1.61–2.36) |
| Crude relative risk (95% CI) |                                | Reference | 1.27 (1.04–1.56) | Reference | 1.09 (0.83–1.41) |
| Model 1: adjusted hazard ratio (95% CI) |                                | Reference | 1.34 (1.10–1.65) | Reference | 1.16 (0.89–1.51) |
| Model 2: adjusted hazard ratio (95% CI) |                                | Reference | 1.28 (1.05–1.58) | Reference | 1.17 (0.89–1.52) |
| Model 3: adjusted hazard ratio (95% CI) |                                | Reference | 1.24 (1.00–1.52) | Reference | 1.17 (0.90–1.53) |

Incidence rate, per 10,000 person-months.
Model 1: including age, sex, marital status, and education.
Model 2: including age, sex, marital status, education, hypertension, diabetes mellitus, and hyperlipidemia.
Model 3: including age, sex, marital status, education, and co-morbidities (hypertension, diabetes mellitus, stable coronary artery disease, hyperlipidemia, congestive heart failure, acute myocardial infarction, rheumatic disease, liver disease, liver cirrhosis, HIV, and tuberculosis).

CI = confidence interval, PSM = propensity score matching.

In conclusion, despite the fact that systemic lymphoma with intraocular involvement may present as uveitis, this 18-year nationwide population-based cohort study showed that the incidence of uveitis after systemic lymphoma was not significantly higher than the PSM group in Taiwan. Nevertheless, the incidence of uveitis is higher than epidemiological data from western countries. In elderly and rheumatic patients with intraocular inflammation, it is important to first exclude uveitis masquerade syndrome, which could be a harbinger of intraocular involvement from systemic lymphoma. An earlier diagnosis is essential to prescribe appropriate treatment and to improve the outcome. Further large-scale prospective clinical studies to investigate whether systemic lymphoma influences the incidence of uveitis are warranted.

Acknowledgments
We thank Dr Jing-Yang Huang and Center for Health Data Science, Chung Shan Medical University Hospital for providing biostatistics consultations.

Author contributions
The authors have no proprietary or commercial interest in any materials mentioned in this article. The authors were involved in design and conduct of study; data collection; analysis, management, and interpretation of data; and preparation, review, and approval of the manuscript.

Conceptualization: Chun-Ju Lin, Yi-Yu Tsai.
Data curation: Chun-Ju Lin, Min-Yen Hsu.
Formal analysis: Pei-Lun Liao, Min-Yen Hsu.
Funding acquisition: Chun-Ju Lin, Min-Yen Hsu, Cheng-Hsien Chang.
Investigation: Chun-Ju Lin, Pei-Lun Liao, Min-Yen Hsu, Cheng-Hsien Chang, Chun-Ting Lai.
Methodology: Chun-Ju Lin, Pei-Lun Liao, Chun-Ting Lai, Ning-Yi Hsia, Huan-Sheng Chen.
Project administration: Chun-Ju Lin, Cheng-Hsien Chang.
Resources: Min-Yen Hsu, Cheng-Hsien Chang, Peng-Tai Tien.
Software: Min-Yen Hsu, Huan-Sheng Chen.
Supervision: Min-Yen Hsu, Peng-Tai Tien, Ning-Yi Hsia, Huan-Sheng Chen, Chun-Chi Chiang, Yi-Yu Tsai.
Validation: Yu-Te Huang, Peng-Tai Tien, Ning-Yi Hsia, Henry Bair, Huan-Sheng Chen, Chun-Chi Chiang, Yi-Yu Tsai.

Visualization: Yu-Te Huang, Chun-Ting Lai, Ning-Yi Hsia, Henry Bair, Chun-Chi Chiang, Yi-Yu Tsai.

Writing – original draft: Yu-Te Huang, Chun-Ju Lin.

Writing – review & editing: Yu-Te Huang, Min-Yen Hsu, Peng-Tai Tien, Chun-Ting Lai, Ning-Yi Hsia, Henry Bair, Huan-Sheng Chen, Chun-Chi Chiang, Yi-Yu Tsai.

References

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Canc 2015;136:E359–86.

[2] Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol 2017;10:1301–7.

[3] Hearne E, Netzer OT, Lightman S. Learning points in intraocular lymphoma. Eye (Lond) 2021;35:1815–2.

[4] Lai J, Chen K, Shi HM, et al. B-scan ultrasound and cytology of the vitreous in primary central nervous system lymphoma with vitreoretinal involvement. Int J Ophthalmol 2019;12:1001–7.

[5] Chen K, Ma Y, Ding T, Zhang X, Chen B, Guan M. Effectiveness of digital PCR for MYD88L265P detection in vitreous fluid for primary central nervous system lymphoma diagnosis. Exp Ther Med 2020;20:301–8.

[6] Salomão DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthal 2013;131:1151–8.

[7] Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999;106:1805–10.

[8] Deangelis LM. Current management of primary central nervous system lymphoma. Oncology (Williston Park) 1995;9:63–71. discussion 71, 75–6, 78.

[9] Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 2009;6:587–97.

[10] Barr CC, Joondeph HC. Retinal periphlebitis as the initial clinical finding in a patient with Hodgkin’s disease. Retina 1983;3:253–7.

[11] Zamiri P, Boyd S, Lightman S. Uveitis in the elderly—is it easy to identify the masquerade? Br J Ophthalmol 1997;81:827–31.

[12] Park S, Abad S, Tulliez M, et al. Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients. Medicine (Baltimore) 2004;83:223–32.

[13] Chan TS, Gill H, Leung AY, Chan WM, Khong PL, KwongYL. Uveitis as the initial manifestation of diffuse large B-cell lymphoma. Am J Hematol 2012;87:198–200.

[14] Harman LE, Margo CE, Roetzheim RG. Uveitis: the collaborative diagnostic evaluation. Am Fam Physician 2014;90:711–6.

[15] Corriveau C, Easterbrook M, Payne D. Lymphoma simulating uveitis (masquerade syndrome). Can J Ophthalmol 1986;21:144–9.

[16] Cimino L, Coassin M, Chan CC, et al. Vitreoretinal lymphomas misdiagnosed as uveitis: lessons learned from a case series. Indian J Ophthalmol 2016;64:369–75.

[17] Bonifazi M, Bravi F, Gasparini S, et al. Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies. Chest 2015;147:778–91.

[18] Waritique L, Jamilloux Y, De Parisot De Berneecourt A, et al. Development of vitreoretinal lymphoma in a patient with sarcoid uveitis. Ocul Immunol Inflamm 2020;28:647–50.

[19] Bichel J, Brincker H. Treatment of pruritis in Hodgkin’s disease and in reticulum cell sarcoma. Scand J Haematol 1965;2:83–90.

[20] Romer FK, Hommelgaard P, Shou G. Sarcoidosis and cancer revisited: a longterm follow-up study of 555 Danish sarcoidosis patients. Eur Respir J 1998;12:906–12.

[21] Wu CH, Chung PI, Wu CY, et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J Dermatol 2017;44:423–30.

[22] Hillerdal G, Nio E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984;130:29–32.

[23] Ungprasert P, Crowson CS, Matteson EL. Influence of gender on epidemiology and clinical manifestations of sarcoidosis: a population-based retrospective cohort study 1976-2013. Lung 2017;195:87–91.

[24] Muto R, Miyoshi H, Sato K, et al. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med 2018;7:5843–58.

[25] Yoo KH, Lee H, Suh C. CISLymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. Int J Hematol 2018;109:395–404.

[26] Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491–500.

[27] Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 2018;26:2–16.

[28] Hwang DK, Chou YJ, Pu CY, Chou P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology 2012;119:2371–6.